Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

The goal of this clinical trial is to learn if Cabergoline (Dostinex), a dopamine agonist which has been widely used to treat hyperprolactinemia, prolactinoma for many years, works to treat nonfunctioning pituitary adenoma (NFPA) in adults. The main questions it aims to answer are: Does cabergoline reduce the size of NFPA effectively when used as primary therapy? Participants will: Be 1:1 randomized into two groups. Either to take cabergoline or none for 48 weeks, Visit the clinic every 12 weeks for checkups and tests, Undergo scheduled imaging studies, Magnetic Resonance Imaging (MRI) to measure the change of tumor size.

NCT Number	NCT07034859
Lead Sponsor	National Taiwan University Hospital Collaborators: National Taiwan University Hospital Beihu Branch, National Taiwan University, National Taiwan University Hospital Hsin-Chu Branch, National Taiwan University Hospital, Yun-Lin Branch
Conditions	Pituitary Adenoma, MRI, RCT
Enrollment	30 participants
Start Date	2024-05-20
Primary Completion	2028-10-30 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-24